Keytruda: USFDA accepts biosimilar application of Zydus and German firm for Keytruda | India News
NEW DELHI: Zydus Lifesciences and Formycon AG, an independent developer of biosimilars, jointly announced that the US Food and Drug Administration (USFDA) has accepted for review the biologics license application (BLA) for a proposed biosimilar to Merck’s Keytruda (pembrolizumab), a key cancer drug. Keytruda is the world’s best-selling biologic medicine with global sales at $16.4…
